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The Release Kinetics of Melatonin 
from Innovative Dosage Forms: 
The Role of the Fractal Geometry 
of the “Vehicle”
Natassa Pippa and Costas Demetzos
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is an antioxidant active pharmaceuti-
cal ingredient with numerous applications as medicine and nutraceutical. Melatonin, 
a hormone synthesized by the pineal gland, has a significant role in the regulation of 
the circadian biological clock. The aim of this chapter is to present the conventional 
solid and liquid forms (i.e., tables, capsules, suspensions, etc.) and the nanoformu-
lations (i.e., liposomes, niosomes, polymeric nanoparticles, chitosomes, calcium 
alginate beads, etc.) of melatonin and to give special attention to its release kinetics 
from the pharmaceutical vehicle. These systems have been designed and developed as 
platforms for the delivery and release of melatonin. In all cases, the controlled release 
of melatonin is the main goal of its loading into drug delivery platforms. Fractal 
analysis is a mathematical tool to quantify nature and physical systems’ complex-
ity. These systems have been characterized as fractal objects, due to their fractional 
dimensions. In this chapter, we are probing the interrelationship between the fractal 
dimension of pharmaceutical vehicle and the release profile of melatonin. Several 
examples will be given in order to understand in depth the reason of controlled-
release profile of melatonin and its added value for the development of a new medi-
cine and/or nutraceutical.
Keywords: nanosystems, drug delivery, kinetics, release, fractals
1. Introduction
According to the Drug and Lactation Database, “Melatonin is the hormone 
produced by the pineal gland that plays a role in regulating sleep and circadian 
rhythm as well as a possible role in gut-brain signaling.” As it is stated in the Drug 
and Lactation Database, melatonin (methoxyindole) is used for the organization 
of the circadian rhythms, especially core temperature and sleep–wake rhythms 
[1]. Melatonin is also characterized as a full-service anticancer agent due to its 
functions: inhibition of initiation, progression, and metastasis phases of tumors 
[2]. Aside from its antioxidant, anticancer, antitumor, anti-inflammatory, antiag-
ing, antidiabetic, antiviral, and neuroprotective activities, melatonin exhibits a 
therapeutic potential in the treatment of asthma, respiratory diseases or infections, 
chronic obstructive pulmonary disease, lung cancer, pleural cavity diseases, as well 
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as vascular pulmonary diseases [3]. Melatonin is also used as a food supplement and 
nutraceutical. The dosage and release profile of melatonin are very crucial factors 
that affect the effectiveness of treatment, especially in older adults [4]. According 
to a recent critical analysis, in older adults, the use of the lowest possible dose 
of immediate-release formulation of melatonin is appropriate to best mimic the 
normal physiological circadian rhythm of melatonin and to avoid prolonged, supra-
physiological blood levels [4].
Melatonin has been encapsulated in different conventional and nanotechnologi-
cal systems [5]. In the majority of the cases, the aim of the incorporation of mela-
tonin into formulations is to achieve controlled or sustained release. The aim of this 
chapter is to present the conventional solid and liquid forms (i.e., tables, emulsions, 
suspensions, etc.) and the nanoformulations of melatonin and to give special atten-
tion to release kinetics from the pharmaceutical vehicle.
Furthermore, fractal analysis is a mathematical tool to quantify nature and 
physical systems’ complexity [6]. Fractals have been observed in powdered drug 
substances, in excipients, and in their mixtures, as well as in semifluid dosage forms 
like gels and emulsions [6]. Fractals have been used to describe the dimensions of 
dosage forms, such as tablets, matrix tablets, and spheres [6]. The application of 
fractal geometry for the quantification of the dimensionality of advanced drug 
delivery nanosystems (aDDnS) recently appeared in the literature [5–6]. For 
example, liposomes, micelles, polymersomes, and other nanosystems are fractal 
objects [6]. Additionally, the fractal and fractional kinetics can model very close 
to the reality the release of drugs from polymeric matrices and other dosage forms, 
both solid and liquid [7–9].
In this chapter, we are going to find the interrelationship between the fractal 
dimension of pharmaceutical vehicle and the release profile of melatonin. Several 
examples will be given in order to understand in depth the reason of controlled-
release profile of melatonin and its added value for the development of a new 
medicine and/or nutraceutical.
2. Dosage forms of melatonin
2.1 Conventional dosage forms of melatonin
Reiter et al. summarized what is known about the function of melatonin in 
the oral cavity [10]. Melatonin is released into the saliva by the acinar cells of the 
major salivary glands and via the gingival fluid [10]. Functions of melatonin in the 
oral cavity are likely to relate primarily to antioxidant activities [10]. A case series 
study revealed that the light level and duration of exposure determine the impact of 
self-luminous tablet on melatonin suppression [11]. Hydrophilic polymer matrices 
composed of hydroxypropyl methylcellulose, xanthan gum, and Carbopol®974P NF 
in different amounts were formulated in tablet forms [12]. These tablets exhibited a 
prolonged-release profile of melatonin [12]. Monolayered and three-layered tablets, 
incorporating nanofibrous mats composed of cellulose acetate and polyvinylpyr-
rolidone loaded with MLT, were prepared and exhibited a prolonged-release profile 
of melatonin, too [13]. The release profile of Circadin® tablets is presented in the 
recent literature. Circadin® is a prolonged-release tablet, the only licensed melato-
nin formulation available in the UK [14]. According to Chua et al., the division of 
tablet into two or four halves did not affect the prolonged-release characteristics 
[14]. We can observe this kinetics in Figure 1. Furthermore, immediate-release 
tablets are available in Greek markets as food supplements. This formulation 
investigation is a composition of natural ingredients, which have a relaxant, 
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anxiolytic, and sleep-inducing action. The active ingredients of the formulations 
are melatonin, L-tryptophan (an important amino acid, which is converted in 
the brain to serotonin (neurotransmitter that contributes to a normal sleep cycle; 
serotonin is sequentially converted to melatonin)), passiflora, valeriana, hawthorn, 
and eschscholtzia that increase GABA levels in the brain. For an immediate-release 
formulation, the amount of drug released should not be less than 80% of the 
labeled amount at 30 minutes [15]. This release profile of melatonin is suitable for 
alleviating certain insomnia-related problems and particularly those arising from 
sleep-onset difficulties [15].
Other conventional dosage forms that are used for the melatonin delivery are 
soft capsule gels [16–17]. Soft gel capsules improved the bioavailability of melatonin 
in humans even when the administered dose was reduced [16]. Considering the 
number of conditions in which melatonin supplementation is recommended, this 
evidence could support a broader use of melatonin in clinical practice, especially in 
the field of nutraceuticals [16]. Sublingual solution and hard capsules of melatonin 
have been also appeared as dosage forms in the literature [17]. The sublingual 
solution was prepared with glycerin, ethyl alcohol, stevia powder extract, and tutti-
frutti flavor. The concentration of melatonin was equal to 10 mg/ml [17]. The hard 
capsules are composed of Methocel E4M and lactose anhydrous, and the amount 
of melatonin was 3 mg per capsule. Both of the aforementioned formulations were 
found to be stable in accelerated conditions [17].
2.2 Advanced drug delivery nanosystems of melatonin
2.2.1 Liposomes and lipid drug delivery nanosystems
Liposomes are bilayers composed of phospholipids [6]. They are used as drug and 
vaccine delivery systems and as cellular membrane models [6]. They are biocompat-
ible and biodegradable [6]. The location of melatonin in 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) model membranes was investigated by several techniques such as small-
angle neutron scattering (SANS) and molecular dynamics (MD) simulations [18]. 
The location of melatonin in those lipid membranes is illustrated in Figure 2 [18]. 
The interactions of melatonin with cellular membrane models can be a road map to 
Figure 1. 
Comparison of dissolution profiles for the release of melatonin from Circadin tablets in an intact, halved, 
quartered, and crushed form (data represented mean ± SD, n = 6) (adapted from [14]). The division of tablet 
into two or four halves did not affect the prolonged-release characteristics.
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elucidate the protective effect of melatonin against the formation of amyloid-beta 
(Αβ) proteins of Alzheimer’s disease [19]. In Figure 2, we can also observe that mela-
tonin is located in the interface between head groups and lipid tails, while cholesterol 
is located parallel to lipid chains [18]. The “stabilizing” effect of melatonin, a natu-
rally occurring hormone produced by the brain’s pineal gland, on phase-separated 
model membranes mimicking the outer leaflet of plasma membranes was also inves-
tigated [20]. For example, melatonin stabilizes the liquid-ordered/liquid-disordered 
phase coexistence over an extended range of temperatures. Melatonin appeared to 
induce re-ordering effects in liposome and Langmuir monolayers [20].
Melatonin-loaded liposomes (MLL) were successfully prepared using rapid 
expansion of supercritical solution technology [21]. The system is composed of 
phosphatidylcholine-cholesterol-melatonin at 20:2:1 molar ratio, and the size of the 
liposomes was found to be around 100 nm [21]. The release kinetics of melatonin 
shows slow-release features in early digestive stages and more through characteris-
tics in later stages of simulated gastric fluids [21]. Furthermore, vesicular (liposo-
mal and nanoencapsulated) forms of melatonin efficiently downregulate sodium 
fluoride-induced rat hepato- and broncho-TNF-α, TGF-β expressions, and associ-
ated oxidative injury, as well as oxidative damage in sodium fluoride (NaF)-treated 
lungs and liver [22]. The nanoencapsulated melatonin was evaluated as a more 
powerful remedial therapy in comparison with liposomes, in terms of its efficacy in 
regulating NaF-intoxicated oxidative injury [22]. Melatonin also encapsulated into 
liposomes produced using supercritical carbon dioxide (an easier technique com-
pared to thin-film hydration method) [23]. The release profile of melatonin is more 
or less the same for the liposomes prepared by the two techniques (i.e., supercritical 
carbon dioxide and thin-film hydration method), but exhibits differences com-
pared to tablets [23].
The hypotensive melatonin analogue 5-methoxycarbonylamino-N-acetyltrypt-
amine (5-MCA-NAT) was loaded into hybrid liposomes (i.e., polymer-grafted 
liposomes). These hybrid formulations were combined with mucoadhesive (sodium 
hyaluronate or carboxymethylcellulose) or amphiphilic block thermosensitive 
(poloxamer) polymers to prolong the release profile of the active ingredient. The 
prepared hybrid liposomes’ size was found to be between 150 to 200 nm with low 
polydispersity and zeta potential near zero. The release profile of the 5-MCA-NAT 
melatonin was found to be dependent on the nature of the polymeric guest. In 
the presence of the polymer, the released ratio of melatonin was also decreased 
Figure 2. 
Schematics illustrating the proposed locations of cholesterol and melatonin in the lipid membrane:  
(A) cholesterol, (B) melatonin. (adapted from [18]).
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in comparison with the pure liposomes. The hypotensive effect of the prepared 
systems was further investigated in rabbit eyes.
Melatonin was also incorporated into chitosomes [24]. Chitosomes are chitosan-
coated liposomes that represent an alternative to conventional liposomes since they 
present better stability and bioadhesivity [24]. Chitosomes are prepared by using 
a different molar ratio of the active ingredient and the polymer. In all cases, the 
amount of the phosphatidylcholine was constant [24]. These formulations exhibit 
size between 200 and 250 nm, with negative zeta potential and encapsulation 
efficiency between 30 and 60% [24]. The amount of chitosan exhibited the key role 
for the stability of the polymer-coated liposomes and their loading properties [24].
Last but not least, melatonin and its structural analogues do not possess antioxi-
dant properties on Fe(2+)-initiated peroxidation of sonicated liposomes made of 
retinal lipids [25]. The in vitro protective effects of melatonin against oxidation of 
1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (PLPC) liposomes and low-
density lipoproteins (LDL; 3 g/L total concentration) by hydroxyl radicals produced 
by water gamma radiolysis were also investigated [26].
Solid lipid microparticles were designed as an oral pulsatile system for the 
delivery of melatonin to pediatric patients [27].
2.2.2 Niosomes
Niosomes are composed of surfactants (Tweens and Spans) and are vesicular 
drug delivery systems. The unique structure of niosome presents an effective novel 
drug delivery system with the ability of loading both hydrophilic and lipophilic 
drugs [28–29]. A transmucosal niosome gel was developed to improve the pharma-
cokinetics of exogenous melatonin [30]. The melatonin niosome gel was character-
ized by several physicochemical techniques, and melatonin levels were determined 
in healthy volunteers [30]. Oral transmucosal melatonin niosome gels, at different 
molar ratio of the active ingredient, topically applied in 14 healthy volunteers in 
a randomized double-blinded crossover design with a 7-day washout, gave dose-
proportional pharmacokinetics, with improved absorption and prolonged systemic 
circulation [30]. Additionally, melatonin-loaded elastic niosomes were prepared 
and lyophilized [31]. The lyophilized niosomal system was incorporated into the 
Pickering emulsion. Ex vivo permeation studies revealed 58% of melatonin were 
permeated through the rat skin while 37% of melatonin accumulated in the skin 
after 24 hours. This formulation is effective for UV-induced skin damage [31].
2.2.3 Polymeric nanoparticles and polymer-based drug delivery nanosystems
Polymeric nanoparticles include a variety of systems composed of polymers. 
The polymers should be biocompatible for drug delivery applications. Generally, 
polymers exhibit nice drug loading and release properties. Some polymers like 
Pluronics® are FDA approved. Pohlmann et al. (2010) have shown that the in vitro 
antioxidant effect of melatonin against lipid peroxidation in microsomes and 
liposomes can be improved by encapsulation of the antioxidant drug in polymeric 
nanoparticles. Polymeric nanoparticles (nanocapsules or nanospheres) have been 
used to improve the melatonin efficacy and release, too [32]. For example, incor-
poration in polymeric nanocapsules improves the antioxidant effect of melatonin 
against lipid peroxidation in mice brain and liver. It should be pointed out that the 
melatonin-loaded polysorbate 80-coated nanocapsules caused a marked reduction 
on lipid peroxidation levels in all studied tissues and increased the total antioxidant 
reactivity in the hippocampus [32].
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Two types of polymeric nanoparticles have been also investigated for ocular 
administration of melatonin [33]. For example, lecithin/chitosan nanoparticles 
with size around 250 nm and Pluronics® F127/chitosan micelles with size around 
20 nm have been designed and developed in order to improve the bioavailability 
of melatonin in the eyes [34]. According to the authors, “the permeability study 
results confirmed the permeation enhancing effect of F127, which was hindered 
in the presence of chitosan. Lecithin/chitosan nanoparticles were characterized by 
prominent mucoadhesive properties and prolonged melatonin release, which was 
shown to control melatonin permeation across an in vitro corneal epithelial model. 
Such properties demonstrate the potential for nanoparticles to provide an extended 
pre-corneal residence time of melatonin, ensuring higher eye-related bioavailability 
and extended intraocular pressure reduction compared to melatonin in both aque-
ous and micelle solutions” [34].
Poly(D,L-lactide-co-glycolide) (PLGA) polymers have been used for the prepa-
ration of nanoparticles and microparticles loaded with melatonin [35–36]. Both of 
them are prepared by the emulsion-diffusion-evaporation method and the addition 
of 0.2% (w/v) melatonin in the aqueous phase. The size of nanoparticles was about 
200 nm and the entrapment efficiency around 14%, while the size of micropar-
ticles was about 3.5 micrometers and the encapsulation efficiency 27% [35–36]. 
The toxicity and the effectiveness of the prepared systems are also evaluated using 
cell lines. According to the results, melatonin could be an adjunct to the routine 
chemotherapy of osteosarcoma by encapsulating it into PLGA polymeric delivery 
platform [36]. Additionally, PLGA nanoparticles and polysorbate 80-coated PLGA 
nanoparticles (PLGA-PS80) increase the in vitro antioxidant activity of melatonin 
[36]. The sizes of the PLGA-PS80 and PLGA nanoparticles were 212 and 187 nm, 
and the encapsulation entrapment of melatonin was 26 and 41%, respectively [37]. 
The release kinetics of melatonin followed the second-order model during studies 
from nanoparticles, while PLGA-PS80 presented more prolonged melatonin release 
[37]. The spherical shape of nanoparticles and the strong interactions due to nega-
tive zeta potential are the possible explanation of the release kinetics of melatonin 
from nanoparticles [37].
Furthermore, melatonin was loaded into chitosan-tripolyphosphate nanoparti-
cles [38]. Melatonin nanoparticles protect against etoposide-induced genotoxicity in 
the HepG2 cell line (etoposide is one of the most effective chemotherapeutic agents 
used in the treatment of various types of tumors) [38]. An increased nose-to-brain 
delivery of melatonin mediated by polycaprolactone nanoparticles for the treatment 
of glioblastoma has been also designed and developed [39]. No cytotoxic effect was 
observed against non-tumor cells [39]. Another interesting formulation of melato-
nin is hybrid hydrogels composed of calcium alginate beads and combinations of 
polymers such as polyvinylpyrrolidone (PVP10000 and PVP55000), hydroxypropyl 
methylcellulose (HPMC15000 and HPMC100000) at different molar weights, lactose 
monohydrate, and as a surfactant sodium laureth sulfate (SLS) [40]. In all cases, 
the encapsulation efficiency of melatonin was very high, around 80% [40]. The 
swelling studies and the release profile were found to be dependent on the pres-
ence of the polymer [40]. Fickian diffusion mechanism and burst release were also 
observed [40]. The nature (architecture and molecular weight) of the polymeric 
guest altered the physicochemical behavior of the calcium alginate beads and the 
release of melatonin, too [40].
2.3 Release kinetics of melatonin from delivery platforms
Melatonin has been encapsulated in different delivery carriers, as mentioned 
above. The majority of these carriers are summarized in Table 1. We should highlight 
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that the reason of the design and the development of different formulations of mela-
tonin is the achievement of its controlled/programmed release. There are systems 
of immediate release of melatonin, i.e., tablets and some others where the release 
of melatonin is prolonged, i.e., polymeric nanoparticles. The treatments of sleep-
onset problems and/or sleep maintenance discomforts are the goals of preparing a 
delivery platform of melatonin as medicine or as food supplement/nutraceutical. 
Recently, a comparative study of the in vitro release of melatonin from matrix tablets 
and liposomal formulation appeared in the literature [41]. The matrix tablets used 
were comprised of HPMC and dextran. Moreover, melatonin was encapsulated into 
conventional liposomes composed of DPPC and dipalmitoyl-phosphatidyl glycerol 
(DPPG), in an attempt to compare the hormone’s release profile from liposomal for-
mulations with its respective release from matrix tablets [41]. Some of the formula-
tions of the matrix tablets and the liposomes exhibit the same release behavior ideal 
for the maintenance of sleep [41]. On the other hand, the burst release of melatonin 
from some other matrix tablet formulations is ideal for the fast sleep onset [41].
In order to design and develop an ideal drug delivery platform combining a burst 
release of melatonin accompanied by a prolonged release, mathematical model-
ing and simulations are needed. In that case, the fractal nature of the formulation 
should be taken into consideration [6–8]. The last one is very important because the 
fractal dimensionality of these systems is closer to their real dimensions [6–8]. Both 
conventional systems like tablets and capsules and nanosystems like liposomes and 
polymeric nanoparticles are fractal objects. In other words, the mechanistic expla-
nation of the release profile of melatonin should be based on the fractal dimensions 
of the drug delivery systems.
3. Conclusions
Melatonin is a chronobiotic hormone used for the treatment of sleep problems 
and disorders. In this chapter, we presented the formulations of melatonin that 
appeared in the literature. Tablets, capsules (hard and soft gels), and the advanced 
drug delivery systems of pharmaceutical nanotechnology offer the possibility of 
encapsulation efficiency of melatonin and ideal release properties. Several routes 
of administration have been proposed, but in the majority of the cases, the per os 
administration is the most popular route of administration, especially of the nutra-
ceuticals. The interrelationship between the fractal dimension of pharmaceutical 
vehicle and the release profile of melatonin is the key point for the development of 
delivery platforms of melatonin as medicines and food supplements/nutraceuticals.
Conventional forms Advanced drug delivery systems
Tablets
• Polymeric matrices
• Three-layered tablets
Liposomes/lipid carriers
• Chitosan-coated liposomes (chitosomes)
• Polymer-grafted liposomes
• Solid lipid microparticles as pulsatile systemSublingual suspensions
Capsules
• Soft gels
• Hard gels
Niosomes
Polymeric nanoparticles
• PLGA nanoparticles and microparticles
• Polysorbate 80-coated PLGA nanoparticles
Table 1. 
The delivery systems of melatonin.
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